Mediplantex National Pharmaceutical JSC (HNX:MED)
Vietnam · Delayed Price · Currency is VND 24,300
+1,000 (4.29%)
At close: Jul 17, 2025
R1 RCM Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2020 |
| 360,486 | 443,136 | 399,965 | 401,051 | 343,951 | 521,391 | Upgrade | |
Revenue Growth (YoY) | -21.88% | 10.79% | -0.27% | 16.60% | -34.03% | -28.43% | Upgrade |
Cost of Revenue | 276,514 | 350,655 | 316,916 | 321,750 | 275,877 | 404,519 | Upgrade |
Gross Profit | 83,971 | 92,481 | 83,049 | 79,301 | 68,074 | 116,872 | Upgrade |
Selling, General & Admin | 66,826 | 70,368 | 68,918 | 70,666 | 59,184 | 89,651 | Upgrade |
Operating Expenses | 66,826 | 70,368 | 68,918 | 70,666 | 59,184 | 89,651 | Upgrade |
Operating Income | 17,145 | 22,113 | 14,130 | 8,634 | 8,890 | 27,221 | Upgrade |
Interest Expense | -22.8 | -2,417 | -5,394 | -5,004 | -3,619 | -5,815 | Upgrade |
Interest & Investment Income | 549.7 | 549.7 | 7,851 | 5,811 | 4,790 | 5,419 | Upgrade |
Currency Exchange Gain (Loss) | -1,138 | -530.32 | - | - | - | - | Upgrade |
Other Non Operating Income (Expenses) | -1,705 | -377.37 | -1,535 | -774.96 | -4,533 | 4,159 | Upgrade |
Pretax Income | 14,829 | 19,338 | 15,051 | 8,666 | 5,528 | 30,984 | Upgrade |
Income Tax Expense | 3,221 | 4,155 | 3,214 | 2,300 | 1,781 | 6,562 | Upgrade |
Net Income | 11,608 | 15,183 | 11,837 | 6,366 | 3,747 | 24,422 | Upgrade |
Net Income to Common | 11,608 | 15,183 | 11,837 | 6,366 | 3,747 | 24,422 | Upgrade |
Net Income Growth | -28.95% | 28.26% | 85.95% | 69.88% | -84.66% | -31.97% | Upgrade |
Shares Outstanding (Basic) | 12 | 12 | 12 | 9 | 6 | 6 | Upgrade |
Shares Outstanding (Diluted) | 12 | 12 | 12 | 9 | 6 | 6 | Upgrade |
Shares Change (YoY) | -5.79% | 0.05% | 32.16% | 49.59% | -0.05% | -0.01% | Upgrade |
EPS (Basic) | 935.19 | 1223.00 | 954.00 | 678.00 | 597.00 | 3889.00 | Upgrade |
EPS (Diluted) | 935.19 | 1223.00 | 954.00 | 678.00 | 597.00 | 3889.00 | Upgrade |
EPS Growth | -24.59% | 28.20% | 40.71% | 13.57% | -84.65% | -31.96% | Upgrade |
Free Cash Flow | - | 34,710 | -84,449 | -91,039 | 7,746 | 60,527 | Upgrade |
Free Cash Flow Per Share | - | 2795.95 | -6805.99 | -9696.32 | 1234.13 | 9638.35 | Upgrade |
Dividend Per Share | - | - | 900.000 | 500.000 | 250.000 | - | Upgrade |
Dividend Growth | - | - | 80.00% | 100.00% | - | - | Upgrade |
Gross Margin | 23.29% | 20.87% | 20.76% | 19.77% | 19.79% | 22.41% | Upgrade |
Operating Margin | 4.76% | 4.99% | 3.53% | 2.15% | 2.58% | 5.22% | Upgrade |
Profit Margin | 3.22% | 3.43% | 2.96% | 1.59% | 1.09% | 4.68% | Upgrade |
Free Cash Flow Margin | - | 7.83% | -21.11% | -22.70% | 2.25% | 11.61% | Upgrade |
EBITDA | 24,835 | 30,019 | 22,574 | 18,654 | 18,426 | 37,241 | Upgrade |
EBITDA Margin | 6.89% | 6.77% | 5.64% | 4.65% | 5.36% | 7.14% | Upgrade |
D&A For EBITDA | 7,689 | 7,906 | 8,444 | 10,020 | 9,536 | 10,020 | Upgrade |
EBIT | 17,145 | 22,113 | 14,130 | 8,634 | 8,890 | 27,221 | Upgrade |
EBIT Margin | 4.76% | 4.99% | 3.53% | 2.15% | 2.58% | 5.22% | Upgrade |
Effective Tax Rate | 21.72% | 21.49% | 21.35% | 26.55% | 32.22% | 21.18% | Upgrade |
Revenue as Reported | 360,486 | 443,136 | 399,965 | 401,051 | 343,951 | 521,391 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.